UPDATE: Wedbush Upgrades Ironwood Pharmaceuticals to Neutral on LINZESS Strength

Loading...
Loading...
Wedbush upgraded Ironwood Pharmaceuticals
IRWD
from Underperform to Neutral and raised the price target from $11.00 to $13.00. Wedbush said, "Early script data for Q1:13 (5 weeks) suggests strong week-over-week LINZESS performance (20,000+ pills per week growth), which, if sustained, would see Q1 and FY:13 end-user demand well ahead of our initial conservative estimates. We are adjusting sales and expense numbers and, as a consequence of our revised outlook, are removing our expectation that IRWD will require an additional $100M equity financing (although additional cash to bolster the balance sheet continues to be in our expectations)." Ironwood Pharmaceuticals closed at $13.58 on Tuesday.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorUpgradesAnalyst RatingsWedbush
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...